scholarly journals Intravitreal Bevacizumab (Avastin) and Panretinal Photocoagulation in the Treatment of High-Risk Proliferative Diabetic Retinopathy

2013 ◽  
Vol 29 (6) ◽  
pp. 550-555 ◽  
Author(s):  
Chang-Sue Yang ◽  
Kuo-Che Hung ◽  
Yi-Ming Huang ◽  
Wen-Ming Hsu
Keyword(s):  
Diabetic Retinopathy ◽  
High Risk ◽  
Proliferative Diabetic Retinopathy ◽  
Intravitreal Bevacizumab ◽  
Panretinal Photocoagulation

scholarly journals Comparison of efficacy of combination therapy of an Intravitreal injection of bevacizumab and photocoagulation versus Pan Retinal Photocoagulation alone in High risk Proliferative Diabetic Retinopathy

2020 ◽  
Vol 37 (1) ◽  
Author(s):  
Rebecca Murtaza Rajar ◽  
Fahad Feroz Shaikh ◽  
Shafi Muhammad Jatoi
Keyword(s):  
Diabetic Retinopathy ◽  
High Risk ◽  
Combination Therapy ◽  
Intravitreal Injection ◽  
Proliferative Diabetic Retinopathy ◽  
Intravitreal Bevacizumab ◽  
University Hospital ◽  
Panretinal Photocoagulation ◽  
Pan Retinal Photocoagulation ◽  
Retinal Photocoagulation

Objective: To compare efficacy of intravitreal bevacizumab augmented with Panretinal photocoagulation versus Panretinal photocoagulation alone in high risk proliferative diabetic retinopathy. Methods: This is Randomized clinical control trial study conducted at ISRA University Hospital, Hyderabad from July 2018 to December 2018. A total of 76 eyes were randomized into two groups, 38 eyes undergone PRP plus intravitreal bevacizumab, while 38 eyes had PRP alone. Status of neovessels was assessed before and after treatment with the help of fundus fluorescein angiography. Neovessels at disc (NVD’s) and neovessels elsewhere (NVE’s) were assessed with the disc surface diameter. Results: Seventy-six eyes were enrolled in this randomized clinical trial into two groups consecutively, that all completed the six months follow-up. In the PRP group mean BCVA (logMAR) worsened significantly from mean 0.30±0.07 to mean 0.40±0.04 at a 30th day and mean 0.40±0.04 at day 90. While BCVA become improved from 0.30±0.05 to 0.1±0.03 at week four and 0.1±0.02 at week 12 in PRP-Plus group. There was significant change in regression of NVES in PRP only group at week 4 is 2.25±0.75 (p=0.00004) and at 12 weeks 2.00±0.50 (p=0.00002), while in PRP + intravitreal bevacizumab group at 4th week was 1±0.5 (p =0.0001) and at 12th week was 0.75±0.25 (p=0.0001). Conclusion: Intravitreal Bevacizumab augmented with PRP is more effective in early regression of neovessels in high risk PDR patients. doi: https://doi.org/10.12669/pjms.37.1.3141 How to cite this:Rebecca, Shaikh FF, Jatoi SM. Comparison of efficacy of combination therapy of an Intravitreal injection of bevacizumab and photocoagulation versus Pan Retinal Photocoagulation alone in High risk Proliferative Diabetic Retinopathy. Pak J Med Sci. 2021;37(1):157-161. doi: https://doi.org/10.12669/pjms.37.1.3141 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study)

2008 ◽  
Vol 86 (4) ◽  
pp. 385-389 ◽  
Author(s):  
Matheus Tonello ◽  
Rogério A. Costa ◽  
Felipe P. P. Almeida ◽  
José C. Barbosa ◽  
Ingrid U. Scott ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
High Risk ◽  
Proliferative Diabetic Retinopathy ◽  
Intravitreal Bevacizumab ◽  
Panretinal Photocoagulation
Sign in / Sign up

Export Citation Format

Share Document